30186-38-0Relevant articles and documents
Rearrangement and cyclisation reactions on the 1-Arylpyrrol-2-iminyl-2-Aryliminopyrrol-1-yl radical energy surface
Borthwick, Scott,Foot, Jonathan,Ieva, Maria,McNab, Hamish,McNab, Lilian,Rozgowska, Emma J.,Wright, Andrew
, p. 161 - 175 (2021/02/02)
Independent generation of the iminyl (X = N) and pyrrol-1-yl (X = N) radicals by flash vacuum pyrolysis of the corresponding oxime ether and N-(dimethylamino) compound, respectively, provides two regioisomeric pyrrolo1,2-A]quinoxalines compounds. This shows that the radical species interconvert via the spirodienyl moeity at high temperatures. Corresponding generation of the pyrrol-1-yl (X = CH) radical gives the pyrrolo[1,2-A]quinoline as the only cyclised product. In this case, DFT calculations suggest that direct cyclisation of the pyrrol-1-yl takes place, rather than formation of the spirodienyl species and exclusive migration of the C-N bond.
N-SUBSTITUTED (ALPHA-IMIDAZOLYL-TOLUYL) PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS
-
, (2008/06/13)
A class of N-substituted (α-imidazolyl-toluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula STR1 wherein m is one; wherein each of R 0 and R 1 is i
N-SUBSTITUTED N-(ALPHA-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS AND USE FOR TREATMENT OF CIRCULATORY DISORDERS
-
, (2008/06/13)
A class of N-substituted N-(α-triazolyltoluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula STR1 wherein m is one; wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R 3, R 4, R 5, R 6, R 7, R 8, R 9 and R. sup.10 is independently selected from hydrido, halo, nitro, trifluoromethyl, hydroxy, alkoxy, cyano, carboxyl and methoxycarbonyl; with the proviso that at least one of R 5 and R 8 must be selected from COOH, SH, PO 3 H 2, SO 3 H, CONHNH 2, CONHNHSO 2 CF 3, OH, STR2 wherein each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.